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Abstract
Background: The WHO has established the disability-adjusted life year (DALY) as a metric for measuring the burden of
human disease and injury globally. However, most DALY estimates have been calculated as national totals. We mapped
spatial variation in the burden of human African trypanosomiasis (HAT) in Uganda for the years 2000–2009. This represents
the first geographically delimited estimation of HAT disease burden at the sub-country scale.
Methodology/Principal Findings: Disability-adjusted life-year (DALY) totals for HAT were estimated based on modelled age
and mortality distributions, mapped using Geographic Information Systems (GIS) software, and summarised by parish and
district. While the national total burden of HAT is low relative to other conditions, high-impact districts in Uganda had DALY
rates comparable to the national burden rates for major infectious diseases. The calculated average national DALY rate for
2000–2009 was 486.3 DALYs/100 000 persons/year, whereas three districts afflicted by rhodesiense HAT in southeastern
Uganda had burden rates above 5000 DALYs/100 000 persons/year, comparable to national GBD 2004 average burden rates
for malaria and HIV/AIDS.
Conclusions/Significance: These results provide updated and improved estimates of HAT burden across Uganda, taking
into account sensitivity to under-reporting. Our results highlight the critical importance of spatial scale in disease burden
analyses. National aggregations of disease burden have resulted in an implied bias against highly focal diseases for which
geographically targeted interventions may be feasible and cost-effective. This has significant implications for the use of
DALY estimates to prioritize disease interventions and inform cost-benefit analyses.
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Introduction
Developed by the World Health Organization (WHO) in the
early 1990s as part of the creation of the Global Burden of Disease
Study (GBD), the Disability Adjusted Life Year (DALY) is a
standardized metric that has been utilized widely in the two
decades since to estimate the global and regional impact of
diseases, set health care priorities, and assess the cost-effectiveness
of targeted interventions. The publication of the first GBD study
established the DALY as a standard metric for evaluating health
outcomes and facilitating comparison between regions, diseases,
and types of burden [1,2]. Comprehensive global burden
assessments have been published regularly, providing a temporal
lens on changing global health burden; the initial report in 1990
was followed by periodic publications throughout the past two
decades, with the 2010 GBD study most recently published in late
2012, and involving significant methodological changes compared
to previous iterations.
The DALY as a global health measure has not been without
controversy, however. Of particular critique have been burden
assessments for neglected tropical diseases (NTDs), predominantly
in sub-Saharan Africa (SSA). In 2010, GBD estimates placed the
total burden of NTDs at about 108.7 million DALYs or 4.4% of
the total global burden of disease and injury [3]. This represents a
significant increase from the GBD estimate in 2002 of 20 million
DALYs or 1.3% of the total global burden of disease and injury
[4]. Other estimates have found that overall, NTDs account for up
to 56.6 million DALYs globally, and 8.6–21.2 million DALYs in
SSA [5]. These estimates are subject to high uncertainty, however,
given a lack of adequate disease data for most NTDs in SSA [6].
The socio-economic impact of NTDs, encompassing various
parasitic and bacterial infections affecting largely poor populations
in tropical regions, has been poorly accounted for by DALY
calculations [7,8]. Despite the value of GBD metrics, therefore, the
utility of DALY calculations for NTDs remains problematic. This
is particularly true for zoonotic NTDs which impose a dual burden
through human illness as well as economic losses to livestock
industries [9]. These limits in assessing human disease burden for
NTDs have been acknowledged with the publication of the first
WHO report on NTDs [10].
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Human African trypanosomiasis (HAT), or sleeping sickness, is
a parasitic, zoonotic, vector-borne infection endemic to SSA. HAT
causes non-specific febrile illness in the early stage, with
progression to neuropsychiatric disturbances in the late stage,
resulting in coma and death if untreated [11]. HAT primarily
affects remote rural communities in SSA. The acute, rhodesiense
form of the parasite is confined to eastern SSA, while the chronic,
gambiense form occurs in western and central SSA [12]. HAT has a
severe impact on affected communities as it causes not only social
and economic losses due to human illness, but also economic losses
from livestock morbidity and mortality caused by the zoonotic
form of the infection [13]. Omission of these indirect impacts also
have implications for prioritization of funding and cost-benefit
estimates for intervention programs. In addition, control measures
– for rhodesiense HAT in particular – need to account for the dual
impact of human and livestock trypanosomosis prevalence [14].
The global incidence of HAT has been estimated at 17 500 cases
annually, and 50 000–70 000 cases from 2000–2005 [15]. Current
GBD estimates show a significant decrease in recent years, from
1.82 million DALYs attributed to HAT globally in 2000, to
829 000 DALYs in 2005 and 560 000 DALYs in 2010 [3].
However, as a zoonotic NTD with highly focal distributions across
the continent, HAT has been difficult to adequately estimate
within the GBD framework. Furthermore, Simarro et al. [16]
highlighted the risks of reduced HAT elimination efforts as a result
of lowered national burden estimates, arguing that burden-driven
decreases in funding for HAT surveillance and control could lead
to disease re-emergence.
Focal or epidemic-prone diseases present a particular challenge
for burden calculation. Uncertainty exists in estimating the
populations at risk, and the use of large geographic units for
assessment poorly reflects spatial heterogeneity of incidence [4,5].
HAT is a focally concentrated disease, occurring in endemic foci
within tsetse-infested zones of SSA, and gambiense HAT in
particular shows significant spatial variation at the micro level
[17]. Disease mapping and spatial analysis has thus long been a
crucial component of HAT surveillance, prevention, and treat-
ment [12]. Due to its focal nature, HAT imposes a particularly
high burden on affected communities, yet ranks poorly in national
or regional burden assessments [18]. The spatial scale for burden
assessments is thus critical to comparative estimates of burden and
assessment of intervention [19]. HAT incidence varies signifi-
cantly in time as well as space. In Uganda, HAT incidence
decreased over the 2000–2009 study period, from 948 cases of
gambiense HAT in 2000 to 99 new cases in 2009. Rhodesiense HAT
showed a similar decrease, from 300 new cases in 2000, peaking
at 473 in 2005, to 129 cases in 2009. The specific incidence of
these cases in areas of Uganda has shifted over time, for instance,
with the movement of rhodesiense foci north into central Uganda,
approaching the gambiense-endemic area [12]. Temporal variation
in HAT must thus also be considered when examining the spatial
distribution of the disease. With some 60–95% of HAT cases
unreported [20–22], and mortality 100% for untreated patients
[23], HAT burden – like many neglected tropical diseases – is
inadequately represented within the country-based GBD frame-
work.
The GBD study assessments are based on nationally aggregated
estimates. Efforts to estimate focal HAT burden have focused on
the community level [24–26]. At the regional level, Odiit et al.
[27] assessed the burden of rhodesiense HAT across Africa and in
southeastern Uganda. While such studies provide valuable
estimates of local burden in highly affected regions, no studies
have yet estimated sub-national burden for an entire country.
National level estimates are critical to inform broader policy-
making and prioritization of interventions. Here we present the
first study to assess spatially-disaggregated HAT burden at the
national level. We focus on Uganda, the only country where both
rhodesiense and gambiense HAT are endemic, and where concerns of
parasite species convergence have raised international concern
and emergency intervention [28–30]. The temporal variation in
HAT incidence in Uganda shows an overall decrease from 2000–
2009. 948 new cases of gambiense HAT were reported in 2000
compared to 99 in 2009; similarly, 300 cases of rhodesiense HAT
were reported in 2000, peaking at 473 in 2005, and decreasing to
129 in 2009. Notwithstanding this decreasing trend, due to the
significant spatial variation in incidence, specific areas of Uganda
have seen HAT foci reduction, emergence, or resurgence over this
time period [12].
The objectives of this study were to estimate the burden in
DALYs of rhodesiense and gambiense HAT in Uganda for 2000–2009
on the sub-national scale, accounting for both reported and
unreported cases, and to map the results by parish and by district
to compare the spatial distribution of burden. Figure 1 shows the
study area and districts affected by HAT incidence during the
study period.
Methods
DALY definition
The disability-adjusted life year (DALY) is a summary health
measure which incorporates both mortality and morbidity, the
former in terms of years of life lost (YLLs) and the latter in years of
life lived with disability (YLDs). Premature mortality is evaluated
based on the age-distribution of mortality attributable to each
condition, using standard model life expectancies. For YLDs, a
disability weighting between 0 and 1, where 0 is equivalent to
perfect health and 1 is equivalent to premature death, is assigned
to a condition to quantify time lived with a disability based on its
severity. When multiplied by incidence and duration of a
particular disease or condition, this makes debilitation as a result
of disease or injury comparable with mortality estimates. Thus,
YLLs and YLDs are summed to estimate total DALYs. Burden is
generally discounted to represent societal time preference and age-
weighted to account for different social roles at different ages.
Finally, DALYs are aggregated at the national level and presented
Author Summary
Since the 1990s the World Health Organisation has
established the disability-adjusted life year (DALY) as a
metric for the burden of human disease and injury.
However, disease burden has primarily been estimated at
the national scale, which does not account for sub-country
variations in burden levels. We used the case of human
African trypanosomiasis (HAT), a highly focal NTD, in
Uganda to calculate and map burden in DALYs. Our results
show that HAT burden is highly sensitive to under-
reporting estimates, and is particularly high in heavily
affected parishes and districts of Uganda. Some districts in
southeastern Uganda had HAT burden rates comparable
to the national burden rates of major infectious diseases
such as malaria and HIV/AIDS. Thus, the spatial scale of
burden estimation is crucial, especially for focal diseases
such as HAT, and national-level estimates may not reflect
the level of impact in afflicted communities. We recom-
mend sub-country burden estimation to identify key areas
for prioritization of disease surveillance and targeted
interventions.
Spatial Analysis of HAT Burden in Uganda
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as summed estimates for each disease or condition present in a
particular country. [31]
GBD framework and HAT
Prior to the GBD 2010 study, GBD DALY estimates used
standard West Level 26 life tables with a female life expectancy at
birth of 82.5 years, a time discount rate of 3% and an age-
weighting function Cxe{bx with parameters C=0.1658 and
b=0.04 [31]. The recently published GBD 2010 study uses a
new standard life table with a life expectancy at birth of 86.0 years,
accounts for comorbidity in calculating YLDs, and does not
discount DALYs over time or employ age weighting [32]. The
revised GBD 2010 calculations estimated a total burden of
168 651 DALYs for HAT in Uganda in 2000, 97 041 DALYs in
2005, and 29 079 DALYs in 2010 [3]. Here, we use the pre-2010
GBD parameters and estimates as the GBD 2010 methods and
results were not fully published at the time of this study.
The 2004 GBD study estimated a total HAT incidence in SSA
of 60 300, combining separate estimates of rhodesiense and gambiense
HAT incidence in which ‘‘completeness of reporting of cases was
assumed to be around 33% for T.b. gambiense and 5% for T.b.
rhodesiense’’ [22]. Published DALY calculations for HAT burden
use a disability weighting of 0.191 for both rhodesiense and gambiense
HAT, and do not distinguish between stages of disease [19].
Furthermore, the GBD 2004 study assumed durations of 5 years
for gambiense HAT and 1 year for rhodesiense HAT. Lastly, the GBD
2004 assumed 85% of cases were untreated with 100% case
fatality, and 15% treated with 5% case fatality. GBD calculations
based on these parameters resulted in a total estimated burden of
59 423 DALYs for HAT in Uganda in 2004 [22]. This is notably
less than the GBD 2010 estimate of 97 041 DALYs for 2005, thus,
estimates using the pre-2010 parameters may be considered
conservative.
DALY formula and parameterization
Burden was calculated using the standard DALY formula as
published in the Global Burden of Disease framework, with several
important modifications (Table 1). We estimated burden using the
DALY formula for an individual:
{
DCe{ba
bzrð Þ2 e
{(bzr)(L)(1z(bzr)(Lza){(1z(bzr)a)
 " #
31½ 
DALYs were calculated using the standard discount rate of 3%
(r=0.03), with and without age-weighting (C=0.1658 and
Figure 1. Study area. Shaded districts in Uganda affected by HAT over the study period, 2000–2009.
doi:10.1371/journal.pntd.0002704.g001
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b=0.04). Since population-specific life tables are appropriate for
regional burden studies, Uganda-specific life tables were used to
provide a regionally specific estimate of burden due to premature
mortality [19,33]. We acknowledge that this would bias our results
towards lower burden estimates relative to GBD DALY totals,
which use standard model life expectancies. However, given that
Uganda life table values were significantly below model expec-
tancies, their use ensured locally representative and conservative
burden estimates. We additionally used HAT-specific parameters
to provide for more accurate burden estimation. See Table 1 for a
full summary of parameters used in DALY calculations. As
proposed by Fe`vre et al. [19], these included parasite- and stage-
specific disability weightings, durations, and mortality rates, in
recognition that the rhodesiense and gambiense forms of HAT, as well
as the early and late stages, have significantly different clinical
manifestations and rates of disease progression [11]. In order to
allow spatially disaggregated burden estimates, DALY burden was
calculated for individual cases. The GBD study calculates burden
based on national incidence totals; DALY estimation for HAT on
a spatially disaggregated sub-national scale has not previously been
calculated.
Data for 2846 cases of rhodesiense HAT and 4026 cases of
gambiense HAT in Uganda were obtained from the WHO Atlas of
Human African Trypanosomiasis [12]. The Atlas has been used to
estimate the population at risk for HAT in SSA [34,35], and
provides standardized and collated data for spatially and
temporally explicit HAT cases across the continent. Atlas data
was collected on historic case incidence for the years 2000–2009.
We note that the incidence of new cases of both gambiense and
rhodesiense HAT declined over this time period [12]. Thus, our
burden estimates reflect historic values and are not meant to
portray the current situation of HAT in Uganda. DALY
calculations were run 100 times, with the modelled case age and
mortality randomly assigned in each iteration. Age data were not
available, so age was randomly assigned based on an existing age
distribution of HAT cases drawn from a sample of cases from
southeastern Uganda [36]. Distribution fitting was conducted
using STATA (StatCorp version 11). The stage-specific age
distributions were modelled with a negative binomial function,
and age was randomly assigned in the DALY model (see Figures
S1 and S2). Uganda-specific life tables were obtained from the
WHO [37]. Life expectancy values for both sexes for 2000 and
2009 were averaged and considered representative of the 10-year
time period (see Table S1). This assumed minimal bias since life
expectancy in Uganda increased fairly steadily over the study
period [37]. Life expectancy also incorporated the sex ratio in
rhodesiense HAT case incidence where 51.6% of cases were male
[36]. Stage categorisation was available for the majority of
reported HAT cases (see Table 2 for a breakdown). Cases with
no stage data available were considered as early-stage in the
DALY calculations, so as to conservatively estimate burden.
Years of Life Lived with Disability (YLDs)
The haemolympathic early stage of HAT manifests in
intermittent fever, headache, swollen lymph nodes, pruritus, skin
lesions, and edema, among other nonspecific symptoms. Late-
stage or meningoencephalitic HAT is characterised by invasion of
the central nervous system, with symptoms including disruptions
to the sleep cycle, neuropsychiatric, and endocrinal disorders
[11,38]. Overall, clinical symptoms are similar for rhodesiense and
gambiense HAT, though the duration and progress of symptoms
differ markedly; rhodesiense progresses from early to late stage and
death typically within weeks to months, while gambiense HAT may
progress over many months to years, with a more chronic course
of infection [11,39,40]. Disability quantification is thus stage-
specific, with late-stage illness implying substantively higher
disability than early-stage illness.
YLDs were calculated for all cases, assuming that all fatal cases
passed through a period of early- and late-stage disability before
death. Disability weightings of 0.21 for early-stage illness and 0.81
for late-stage illness were used for rhodesiense HAT as per Fe`vre et
al. [25]. Stage-specific disability weightings have not been
estimated for gambiense HAT. Weightings of 0.191 for early-stage
illness and 0.81 for late-stage illness were thus used, based on
estimates in the GBD study [22] and published estimates for
rhodesiense HAT, respectively. These estimates reflect broadly
similar clinical features for the two parasites despite different rates
of progression, although some differences exist, with gambiense
HAT generally being clinically milder and more variable [11].
The average duration of illness was estimated as 6 months for
rhodesiense HAT, with 3 months of early stage and 3 months of late
stage illness. This was based on various published estimates: 21
days for early-stage illness and 61 days for late-stage illness pre-
admission [41], a median survival time of 4 months in the early
1900s epidemic in Uganda [42], 6 months average total duration
Table 1. Summary of parameters used in DALY formula.
Parameter DALY formula Value(s) Comments Source(s)
Age (a) YLLs and
YLDs
Assigned based on negative
binomial function
Assumed age distribution of gambiense
HAT cases equal to rhodesiense HAT cases
[36], see Figures S1 and S2
Duration of
illness (L)
YLDs rhodesiense HAT: 0.25 (early),
0.25 (late); gambiense HAT:
2 (early), 1 (late)
Estimated based on multiple sources; did
not account for variability in disease
duration or early treatment and diagnosis
rhodesiense HAT: [39,41,43];
gambiense HAT: [24,40]
Disability
weight (D)
YLDs rhodesiense HAT: 0.21 (early),
0.81 (late); gambiense HAT:
0.191 (early), 0.81 (late)
Stage-specific weights have not been
derived for gambiense HAT; assumed
similar to late-stage rhodesiense HAT
[22,25]
Mortality YLLs Assigned based on quadratic function,
adjusted for average mortality rates of:
rhodesiense HAT: 2.4% (early), 8.1% (late);
gambiense HAT: 1% (early), 3% (late)
Broadly conservative estimates, to
account for varying mortality of
different HAT treatment regimens
[36,44], see Figure S3
Life expectancy
(L)
YLLs Uganda life tables Assumed rate of life expectancy increase
in Uganda relatively steady from 2000–
2009; accounted for case sex ratio
[37], see Table S1
doi:10.1371/journal.pntd.0002704.t001
Spatial Analysis of HAT Burden in Uganda
PLOS Neglected Tropical Diseases | www.plosntds.org 4 February 2014 | Volume 8 | Issue 2 | e2704
[39] and 2–3 months late-stage duration in patients from
Tanzania and Uganda [43]. The average duration for gambiense
HAT was estimated to be 2 years for early-stage illness and 1 year
for late-stage illness, based on estimates of 36 months early-stage
and 12 months late-stage by Lutumba et al. [24] and 526 days
early-stage and 500 days late-stage by Checchi et al. [40]. Burden
calculation was done regardless of the point of diagnosis, in order
to account retroactively for HAT impact prior to treatment.
Cases were assumed to present at the beginning of early- or late-
stage illness. Thus, YLD calculations included pre-diagnosis
morbidity.
Years of Life Lost (YLLs)
Age-specific mortality was modelled using a quadratic function,
with average mortality adjusted based on parasite type and disease
stage (see Figure S3). Average mortality was estimated at 2.4%
(early stage) and 8.1% (late stage) for rhodesiense HAT [36]. This is
consistent with estimated case fatality rates of 8.4–9.3% for
melarsoprol-treated late-stage rhodesiense HAT in Tanzania and
Uganda [43]. Treatment-based case-fatality ratios (CFRs) have
been estimated for late-stage gambiense HAT cases in the late 1990s
and early 2000s [44]. Based on this, an average mortality rate of
3% was used for late- stage gambiense HAT. Most cases of gambiense
HAT in northwestern Uganda prior to the mid-2000s were treated
with melarsoprol, with a mortality rate of 5–5.9% [44,45].
However, Uganda changed its first-line treatment from melarso-
prol to eflornithine (1.2% mortality) treatment in 2002 [44,46].
Furthermore, the newer nifurtimox-eflornithine combination
therapy was tested in various sites in Uganda during the study
period [47], and shows promise as a lower-mortality treatment
regimen for late-stage gambiense HAT [16,48]. Thus, a reduced
late-stage mortality rate of 3% was used as a conservative estimate.
Negligible published data on early-stage mortality for gambiense
HAT exist; a figure of 1% was used as an estimate since the
mortality for early-stage gambiense illness is known to be low, as
treatment-related complications due to pentamidine administra-
tion rarely occur [11,38].
These stage- and parasite- adjusted mortality distributions were
used to assign the age-specific probability of death in each iteration
of the DALY model. YLLs were calculated only for those cases
that were randomly assigned as deaths, based on the age-specific
mortality probability.
Unreported DALYs
We use the term ‘under-reporting’ herein to refer to the
proportion of the estimated total number of cases which are not
detected by active or passive screening. This lack of detection of
HAT cases is known to be significant, yet remains poorly
estimated. For rhodesiense HAT, a model of under-reporting based
on the early to late stage ratio of presenting cases has estimated
that approximately 40% of cases go unreported – and die – in
Uganda [21,49]. For gambiense HAT, the level of under-reporting
has not been directly estimated. Robays et al. [20] estimated the
effectiveness of active case-finding and treatment in the DRC at
less than 50%, and Lutumba et al. [24] subsequently used this
work to estimate that 40% of gambiense HAT cases in a rural
community of the DRC went undetected following one round of
active screening. Burden estimates are limited by the need to
properly quantify HAT under-reporting [19], particularly as
disease surveillance is lacking in many HAT-endemic areas
[50,51]. Thus, while an under-reporting level of 40% was used
when DALYs were estimated and mapped by parish, we
conducted a sensitivity analysis, varying the reporting rate to
account for the significant uncertainty regarding levels of HAT
under-reporting.
In the sensitivity analysis, the rate of under-reporting was varied
in order to determine the effect on the magnitude and distribution
of burden. For each reported case, the number of cases unreported
was estimated based on various proportions of unreported cases:
0%, 20%, 40% for both parasites, as well as 67% (gambiense) and
95% (rhodesiense) based on the 2004 GBD study [22]. As described
above, 40% was taken as a conservative estimate of the actual
under-reporting rate when summing and mapping DALY totals by
parish. All unreported rhodesiense HAT cases were assumed to be
untreated and 100% fatal. Unreported gambiense HAT cases were
assumed to be 50% fatal. The average duration of a gambiense HAT
case is 3 years [40], and cases of gambiense HAT which remain
undetected following one active screening round could in practice
be detected in subsequent active screening rounds or through
passive detection [24]. Because of the long duration of illness and
possibility of subsequent detection, the 50% mortality estimate for
unreported gambiense HAT conservatively accounts for the
likelihood that a significant proportion of undetected cases may
not in fact lead to fatality. Thus, early- and late-stage YLDs were
calculated for all unreported cases, and YLLs were calculated for
Table 2. Burden of reported HAT cases in Uganda, 2000–2009.
Rhodesiense HAT Gambiense HAT
Summary of reported cases: Number (%)
Total 2846 (100.00) 4026 (100.00)
Early stage 1077 (37.84) 1077 (26.75)
Late stage 1395 (49.02) 2106 (52.31)
No stage 374 (13.14) 843 (20.94)
DALY model:
Mean age 30.25 30.16
Total deaths 150.81 (5.3% mortality) 86.31 (2.1% mortality)
YLDs 451.7 3894.2
YLLs 3641.7 1891.6
DALYs (age-weighted) 4158.6 5785.8
DALYs (without age-weighting) 3407.8 4747.4
doi:10.1371/journal.pntd.0002704.t002
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all unreported rhodesiense and 50% of unreported gambiense cases.
We assumed that all fatal unreported cases passed through the full
disease duration before death. Case age for unreported cases was
assigned independently of the reported case ages, using the late-
stage age distributions and methods described above.
Burden comparison and mapping
Geographic location in latitude and longitude coordinates was
available in the WHO dataset, with the exclusion of 78 rhodesiense
cases and 23 gambiense cases which were missing latitude/longitude
values. Furthermore, 8 rhodesiense HAT cases were identified as
exported, as they represented patients who had migrated outside
of HAT transmission zones. These were excluded to restrict the
analysis to areas of active HAT transmission. These exclusions
resulted in a total of 2760 rhodesiense and 4003 gambiense HAT cases
which were mapped and analysed in ArcGIS (ESRI version 10).
DALY totals for 2000–2009 were mapped and summarised by
parish, the smallest administrative unit in Uganda. District
population data were obtained from the 2002 Uganda census
and projected to 2009 in the UN COD-FOD Registry [52].
Population values were averaged for the period 2002–2007 to give
estimates representative of the study period.
DALY totals were averaged over 2000–2009, and divided by
district population data to give values in terms of DALYs per
100 000 persons per year. This enabled comparison of the relative
burden across districts with the national burden rates for HAT and
other infectious diseases in Uganda, based on the DALY rates
published in the 2004 GBD study [22].
Results
Burden of reported cases
Table 2 summarises the total burden attributable to reported
HAT cases in Uganda, summed over the period 2000–2009.
Results estimated a total of 4159 reported DALYs for rhodesiense
HAT in southeastern Uganda from 2000–2009 (an average of 1.46
DALYs per case). The majority (88%) of the burden resulting from
reported cases was due to years of life lost, with 12% of the burden
due to years of life lived with disability. The total burden for
gambiense HAT in northwestern Uganda was estimated at 5786
reported DALYs (an average of 1.44 DALYs per case). In contrast
to rhodesiense, the majority (67%) of the burden of gambiense HAT
resulted from years of life lived with disability. This is attributable
to the longer duration and lower mortality rates of chronic
gambiense HAT, whereas the acute, high-mortality rhodesiense form
tends to progress more quickly and results in a greater burden due
to mortality.
Sensitivity to under-reporting
As shown in Table 3, model results are highly sensitive to
reporting rate, particularly for rhodesiense HAT. When under-
reporting was accounted for, unreported DALYs formed the bulk
of the total burden. Total burden for unreported cases was high for
both forms of HAT, with overall burden being higher for gambiense
HAT. DALY totals for rhodesiense HAT for 2000–2009 ranged from
less than 4200 DALYs with 0% of cases unreported, to
approximately 54 000 DALYs with 40% of cases unreported
and well over 1 million DALYs with 95% of cases unreported. For
gambiense HAT, total DALYs ranged from less than 5800 DALYs
with 0% under-reporting, to approximately 44 000 DALYs with
40% under-reporting and 123 000 DALYs with 67% under-
reporting. The average annual DALY total when 40% of cases
were assumed as unreported was 9 814 DALYs, resulting from an
estimated average of 1 145 cases per year. This is significantly
lower – approximately one-quarter – when compared to the
existing GBD estimate of 59 423 DALYs. When GBD estimates of
under-reporting were used, however, the annual average burden
was more than double the GBD 2004 estimate at 136 287 DALYs,
resulting from an estimated total incidence of 6 912 cases per year.
Thus, the bulk of this burden resulted from unreported mortality
of rhodesiense HAT.
Spatial and temporal variation in burden
Spatial variation in burden was significant for both forms of
HAT, with cases highly focally concentrated in a small number of
parishes. This is shown by the parish-level burden map in Figure 2.
In the rhodesiense-endemic areas of central and southeastern
Uganda, 413 parishes in total were affected by rhodesiense HAT.
62% of parishes had fewer than 5 reported DALYs, while 5
parishes (1.2%) were afflicted by over 100 DALYs, and these 5
parishes accounted for 21.3% of the burden of reported cases. In
northwestern Uganda, 189 parishes were affected by gambiense
HAT. 25% of parishes had less than 5 reported DALYs, while 12
parishes (6.3%) were afflicted by over 100 reported DALYs,
accounting for 39.4% of the burden of reported cases. Similarly,
when total burden was calculated with 40% under-reporting, 2
parishes in southeastern Uganda, Alwa and Kateta, accounted for
over 2000 DALYs each, forming over 9% of the total burden. In
northwestern Uganda, 2 parishes accounted for over 2000 DALYs
each. A large portion of the burden of gambiense HAT was
concentrated in a few severely afflicted parishes, whereas the
burden of rhodesiense HAT was more geographically widespread
across a greater number of parishes.
Temporal variation in burden over the 2000–2009 period also
showed an overall decreasing trend, reflective of the decrease in
overall HAT incidence. These temporal trends varied by parish
and district, as shown in Figure 3 and Table 4. The most highly
affected areas varied over time. For instance, in the district of
Kaberamaido in central Uganda, foci of HAT burden did not
occur until 2003, showed a peak in the middle of the time period,
and burden was decreasing as of the late 2000s. On the other
hand, districts such as Iganga and Bugiri in southeastern Uganda
showed a marked decrease in HAT burden over the same ten-year
time period.
Table 3. Total HAT burden in Uganda for 2000–2009 in age-
weighted DALYs, with sensitivity analysis of the under-
reporting rate.
Rhodesiense HAT Gambiense HAT Total HAT
Under-reporting
rate: Cases DALYs Cases DALYs DALYs
0% 2 846 4 159 4 026 5 786 9 944
20% 3 558 22 803 5 033 20 222 43 025
40% 4 743 53 828 6 710 44 313 98 141
Annual average 9 814
GBD 2004 under-reporting rates:
67% – – 12 200 123 199
95% 56 920 1 239 672 – –
Total 1 362 871
Annual average 136 287
GBD 2004 estimate 59 423
doi:10.1371/journal.pntd.0002704.t003
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Figure 4 shows that while 8 out of 25 affected districts (32%) had
a lower rate of HAT burden than the national GBD estimate of
212 DALYs/100 000 persons/year, 6 districts had a burden rate
comparable to the national burden rate for tuberculosis, 3 districts
had a burden rate comparable to malaria, and one district had a
burden rate larger than the national average for HIV/AIDS. We
emphasise that the annual average 2000–2009 burden values
shown in Figure 3 reflect past incidence. Given the declining trend
in both forms of HAT incidence in Uganda, current annual
burden rates are likely to be lower than shown. These results must
be further qualified, by the fact that district burden rates for
tuberculosis, malaria, and HIV/AIDS, which have not been
estimated, would likely exceed national averages in highly affected
areas, some of which could overlap with HAT-endemic regions.
The most highly afflicted districts, Kaberamaido and Soroti,
were located in the northern area of the rhodesiense HAT
transmission zone in central Uganda. Kaberamaido had a lower
annual average DALY total (21 381) than Soroti (28 475) and
Iganga (28 404), but also represented a smaller district population.
Dokolo and Iganga, also rhodesiense HAT-endemic districts in the
southeast, had the 3rd and 4th highest DALY rates, respectively.
Moyo was the gambiense HAT-endemic district with the highest
DALY rate and 5th overall, with an annual average total of 5 048
DALYs and a DALY rate of 2 144 DALYs/100 000 persons/
year. Notably, district DALY rates do not account for within-
district spatial variation in burden. As discussed above and
demonstrated in Figures 2 and 3, burden varies significantly across
parishes. Thus, parish-level per capita burden would be higher
than district DALY rates in the most highly affected parishes.
Discussion
Our results encompass new HAT burden estimates for Uganda ,
incorporating revised parameters reflecting the stage- and parasite-
specific determinants of burden. They highlight thehigh sensitivity
to under-reporting, and sub-national spatial variation in burden,
which is inadequately captured by global burden estimates.
Mortality was the main contributor to DALY burden for rhodesiense
HAT but morbidity the main component of gambiense HAT
burden. This is due to the distinct clinical features of the two stages
of disease morbidity, as well as the differential durations and
mortality rates for the two forms of the disease. While the GBD
2004 update distinguishes between disease durations, it does not
distinguish stage-specific disability weightings for either form, nor
does it account for the differences in mortality rates between the
two forms of HAT. Moreover, certain parishes and districts in
Uganda were found to bear an extremely heavy burden due to
HAT morbidity and mortality. Critically, this focality in burden
has not been accounted for by past national burden estimates.
The significant spatial variation in DALY burden across parishes
demonstrates the value of evaluating the burden of focalised diseases
such as HAT on a sub-national scale. While the national total
burden of HAT was low relative to other conditions, highly-affected
districts in Uganda, particularly Kaberamaido, Soroti, Dokolo, and
Iganga in the southeast, and Moyo in the northwest, had per capita
burden levels comparable to or higher than HIV, malaria, and
tuberculosis. It is important to note, however, that the sub-national
burdens of these diseases could also vary across geographic areas
and sub-populations. Hence, similar spatial burden rate evaluation
for other conditions, besides HAT, is merited for a district-level
comparison. Nonetheless, comparison with national burden rates
shows that HAT burden operates on a local level at a scale similar to
the estimated and acknowledged high impacts of HIV, malaria, and
tuberculosis in the country as a whole. Cost-benefit analysis of
intervention in these highly affected regions may be particularly
favourable for focal diseases when local burden and geographically-
targeted interventions are taken into account.
We note several potential sources of bias and limitations to this
study.
Temporal variation
HAT is not only spatially but also temporally focal, occurring in
epidemics of high transmission and incidence [11]. We have
included estimates of parish- and district-level burden sub-divided
into total annual burden for periods of two to three years, but note
that other results presented herein are estimated totals and average
yearly values for 2000–2009, which do not reflect the overall change
in HAT incidence over time or the variation in incidence from year
to year. In order to reflect the current burden situation in the
affected districts of Uganda, updated spatial data on HAT incidence
would be necessary. In addition, temporal variation in HAT would
imply burden rates higher than those presented here since disease
burden will be concentrated during epidemic years. Both spatial and
temporal variation in HAT burden show the concentration of
disease impact in those communities bearing the brunt of the
burden of focal HAT epidemics.Accordingly, the potential benefits
of targeted interventions in these areas will also be greater..
Spatial variation
We have used case incidence data to map the burden of HAT in
Uganda at a spatially specific sub-national scale. However, data on
spatial variation in other model parameters, such as the age of
incidence, mortality, or under-reporting rates (discussed below),
were not available. Hence, the spatial variation in burden
Figure 2. Total HAT burden in Uganda by parish, 2000–2009.
Shaded parishes indicate the total burden in DALYs estimated over the
ten-year study period, as modelled with an under-reporting rate of 40%
[21].
doi:10.1371/journal.pntd.0002704.g002
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identified reflects that of incidence. Nonetheless, this method to
derive HAT burden values from incidence allows DALYs to be
compared across parishes or districts, or with other conditions at
varying spatial scales. Burden units enable this comparison, which
would not be possible from examining disease incidence alone.
Under-reporting
Under-reporting of fatal cases has been noted previously as an
important contributor to the DALY burden of HAT, but has not
been quantified adequately in burden calculations [19]. When
estimates of the proportion of unreported cases were included,
there was a greater than 4-fold increase in burden with 20%
under-reporting, and a nearly 10-fold increase in burden with 40%
under-reporting. These increases were greater for rhodesiense HAT
due to 100% mortality of unreported cases, with a greater than 5-
fold and nearly 13-fold increase in burden with 20% and 40%
under-reporting, respectively. Gambiense HAT showed more
modest increases of 3.5- and 7.7-fold when 20% and 40%
Figure 3. Temporal variation in HAT burden by parish, 2000–2009. Total DALYs per year, as modelled with an under-reporting rate of 40%,
are shown as averaged over the 2000–2009 historical period, and four sub-periods. DALYs/year were calculated and mapped by parish, and district
boundaries are shown.
doi:10.1371/journal.pntd.0002704.g003
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under-reporting was accounted for. Notably, these results are likely
conservative given that Uganda’s national sleeping sickness
program shifted in 2005 from active to passive surveillance,
resulting in reduced reporting [36]. Thus, average under-reporting
rates for the study period of 2000–2009 may have been even
higher than estimated.
Under-reporting estimates have only been validated for
rhodesiense HAT in southeastern Uganda, however, and may not
be applicable for gambiense HAT in the northwest. Because of the
milder and more varied clinical course of the natural progression
of gambiense HAT, cases are typically detected through active case-
finding. Though estimates of gambiense HAT under-reporting are
lacking, surveillance activities have been shown to have poor
sensitivity. Robays et al. [20] used a model to show that active
case-finding and treatment failed to detect a significant portion of
gambiense HAT cases, and Lutumba et al. [53] found that gambiense
HAT screening failed to avoid more than 60% of deaths in the
DRC.
Broad under-reporting estimates also inadequately account for
spatial variation in under-reporting related to the presence of
HAT treatment centres. As discussed above, data on spatial
variance for input parameters such as the under-reporting rate
would strengthen the findings of this study. The proportion of
early-stage patients detected was shown to be inversely related to
distance from health unit by Odiit et al. [54]. However, it is
difficult to define the causation between reported case incidence
and the presence of treatment centres, as facilities are often
deployed in response to sleeping sickness outbreaks.
Efforts to quantify DALY burden due to HAT in Uganda
remain constrained by a lack of robust local estimates of HAT
under-reporting. The importance of improved and sustained
disease surveillance efforts, notwithstanding recent reductions in
reported HAT incidence, has been widely emphasized in order to
promote control and elimination of HAT in endemic areas
[16,30,55,56]. This study demonstrates their further importance in
order to better account for the under-reported burden of HAT.
Disease duration
Broad duration estimates were used for each stage and form of
the disease. This could overestimate duration for patients
diagnosed and treated early in the disease progression. However,
significant delays (median 7 months) in patient presentation and
diagnosis for gambiense HAT have been observed [57], which
underscores the improbability of early case detection and
treatment. Significant variability in disease duration can exist,
particularly in the case of gambiense HAT [58], while varied disease
severity and progression rates between foci have been observed for
rhodesiense HAT in Uganda [59].
Furthermore, YLDs were calculated for all fatal as well as non-
fatal cases, assuming all fatal and all unreported cases passed
through the full early- and late-stage duration. This may have
resulted in an overestimate of burden if cases died in the early
Table 4. DALYs per year by district, showing temporal trends in HAT burden calculated with a 40% under-reporting rate, averaged
over 2000–2009 and four sub-periods.
DALYs/year
District 2000–2009 2000–2002 2003–2004 2005–2006 2007–2009
Adjumani 403.4 628.8 560.6 231.6 187.7
Amuru 40.1 45.4 74.2 5.5 35.1
Arua 1604.6 2884.4 1612.0 1191.0 595.6
Bugiri 239.4 308.6 277.1 351.6 70.2
Busia 122.0 102.0 306.7 101.7 32.4
Dokolo 291.1 0.0 155.9 556.1 495.5
Iganga 1073.7 1604.7 1014.0 1670.9 184.4
Jinja 70.8 103.8 105.3 73.5 13.1
Kaberamaido 821.3 0.0 1154.0 1609.1 895.5
Kalangala 5.6 0.0 0.0 18.0 6.6
Kamuli 608.6 1468.3 569.7 243.4 18.3
Katakwi 2.0 6.8 0.0 0.0 0.0
Kayunga 5.8 7.0 18.4 0.0 0.0
Kumi 11.6 6.2 29.2 19.6 0.0
Lira 39.9 0.0 19.1 141.2 26.0
Mayuge 193.3 296.6 244.2 249.3 18.7
Mbale 5.3 5.8 9.3 8.4 0.0
Moyo 1785.0 2431.3 2718.2 1644.0 610.5
Mukono 275.5 403.0 335.9 291.3 97.1
Pallisa 59.6 19.4 40.2 19.0 139.7
Soroti 1097.1 1275.6 1759.8 1190.5 414.6
Tororo 297.0 841.4 155.6 46.5 13.9
Wakiso 1.8 6.0 0.0 0.0 0.0
Yumbe 574.0 1145.7 436.6 340.1 249.8
doi:10.1371/journal.pntd.0002704.t004
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stage or did not progress through the full late-stage duration.
However, our duration estimates were based on multiple
published estimates and were shorter than the 1-year (rhodesiense)
and 5-year (gambiense) estimates used by the GBD 2004 study [22],
thus may be considered conservative.
Mortality
Mortality estimates for gambiense HAT are highly dependent
on the treatment used. Information on treatment and mortality
were not included in the dataset, which limited the accuracy of
the gambiense mortality estimates. Furthermore, the treatment
regimen traditionally used for late-stage gambiense HAT is
melarsoprol, and a high incidence of melarsoprol treatment
failures for gambiense HAT has been recorded in Uganda [60].
However, lower-mortality eflornithine and combination therapy
treatments were introduced and tested in Uganda throughout
the study period [44,46,47]. Thus, lack of data on treatment
and shifts in treatment regimens led us to conservatively
estimate gambiense HAT mortality based on published case-
fatality ratios.
In addition, 100% and 50% fatality of unreported cases was
assumed for rhodesiense and gambiense HAT, respectively, with all
unreported cases progressing through early and late stages.
However, this would overestimate burden if cases spontaneously
recovered or were trypanotolerant. Recent research has indicated
the possibility of recovery for gambiense HAT in West Africa [61]
but not rhodesiense HAT. However, previous research concluded
that self-resolving and trypanotolerant gambiense HAT infections, if
they do occur, are a small minority [23]. The possibility and
frequency of non-fatal gambiense HAT occurrence remains
unresolved, but seems unlikely to significantly impact HAT
burden estimates.
Burden parameterization
The GBD 2010 study was published in late 2012, and presented
revised methods for DALY calculations. See Text S1 for a full
discussion of the differences in burden parameters and their
potential effect on the results of this study. Notwithstanding these
changes, we identify key priorities for estimation of burden
parameterization for HAT:
1. Disease and stage-specific disability weightings
1. The use of a single disability weighting of 0.191 for HAT
illness, without distinguishing between stages or forms of the
parasite, represents a significant constraint to burden estima-
tion. Late-stage HAT involves a severe neuropsychiatric
disorder which imposes significant limitations on patients’
activities, compared to the nonspecific symptoms of early-stage
Figure 4. Comparison of average annual DALY rates for HAT and other infectious diseases. The calculated historic average annual DALY
rates by district population over the period 2000–2009 are shown in grey. The calculated national average DALY rate for HAT and 2004 GBD DALY
rates for HAT and major infectious diseases in Uganda are shown in black. Estimates of completeness of case reporting for HAT (33% gambiense, 5%
rhodesiense) and DALY rates for other diseases are taken from the GBD 2004 report [22].
doi:10.1371/journal.pntd.0002704.g004
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illness. Furthermore, the current disability weight does not
reflect differences between rhodesiense and gambiense HAT.
1. Disability weightings were re-evaluated for the GBD 2010
update using a combination of household and open-access
online surveys [62]. However, the new weights derived have
not accounted for the stage- and parasite-specific parameters of
HAT infection. Instead, HAT has been grouped with other
infectious diseases, with weight estimates of 0.005, 0.053, and
0.210 for mild, moderate, and severe acute episodes,
respectively [63]. These disability weightings are therefore less
specific to HAT and do not fully reflect the debilitating
symptoms of the stages and types of HAT illness.
2. Duration of sequelae
2. The use of broad estimates of 5-year duration for gambiense
HAT and 1-year duration for rhodesiense HAT do not account
for the differential durations of disease stages. In combination
with stage-specific disability weightings, a breakdown of HAT
illness duration by stage would provide for more accurate
burden estimation.
3. Parasite- and treatment-specific mortality rates
3. The GBD mortality estimates do not reflect differential
mortality rates for rhodesiense and gambiense HAT and their
associated treatments, but the two forms of HAT disease have
markedly different clinical courses and outcomes. Mortality for
the acute rhodesiense HAT and treatment with the melarsoprol
regimen are higher than for gambiense HAT and the recently
developed eflornithine or drug combination therapies [44,46].
To accurately determine HAT burden, further data on the case
fatality rates associated with particular treatment regimens and
on the actual deployment of various treatments in the study
area and time period of interest are required.
4. Spatially disaggregated burden
4. Most importantly, national-level burden estimates, though
useful tools for global assessment of relative disease burden, do
not reflect the focalization of spatially heterogeneous disease
incidence for infections such as HAT.
Limitations to burden parameterization are not unique to HAT.
Parameters have been developed in varying levels of specificity for
other diseases. For instance, GBD 2004 disability weightings for
tuberculosis, malaria, and HIV/AIDS vary with age; weightings
for malaria and HIV/AIDS also distinguish three separate disease
sequelae and vary with treatment. Methods for estimating
mortality rates vary across these three conditions, although none
share the parasite- and treatment- specific issues related to HAT.
While acknowledging that these varied assumptions underlie the
DALY estimates used for broad comparison with other diseases,
an in-depth evaluation of the GBD parameters for these diseases is
beyond the scope of this study. It is critical that the public health
research community move beyond the GBD framework’s focus on
nationally aggregated burden to consider spatial – and temporal –
variation in burden. This is particularly relevant for neglected
tropical diseases whose current burden values are already poorly
estimated [5,7]. While national estimates remain a useful tool for
systematic comparison of global trends, their use for prioritization
of health intervention and funding has failed to consider the scale
dependence of disease burden. While absolute DALY burden may
be relatively low for focal diseases, the cost-benefit ratio of
intervention measures targeted at small areas of high burden may
be favourable compared to diseases with geographically dispersed
burden. Sub-national burden evaluation for a range of conditions
may allow quantitative comparison of the spatial variation in
burden across diseases. This would also allow identification of
those areas and populations suffering from highly focalized
impacts and hence the greatest potential benefits of targeted
interventions. This is especially imperative since we suspect HAT
is not the only disease that shows a focalized burden, and further,
multiple diseases may impact the same local populations and merit
more general public health practices or combined interventions.
Burden estimates are established as a valuable guide to directing
scarce disease control resources, yet in many cases disease
surveillance and health policy interventions operate at local levels.
In compliment to the recent methodological revisions to the GBD
study, it is thus imperative that the use of the DALY also be
revised to validate and test its utility at differential spatial scales.
Supporting Information
Figure S1 Probability distribution for early-stage case
age. A negative binomial function was fit to the age of 942 early-
stage HAT cases [36] using the nbfit function in STATA 11
software. Parameters (standard error): p = 0.92958 (0.00351),
r = 2.45125 (0.12014), m=32.35775 (0.69842). This probability
distribution was used to assign age to early-stage cases from the
WHO Atlas of HAT dataset when modelling DALY burden.
(TIF)
Figure S2 Probability distribution for late-stage case
age. A negative binomial function was fit to the age of 1426 late-
stage HAT cases [36] using the nbfit function in STATA 11
software. Parameters (standard error): p = 0.92535 (0.003),
r = 2.4361 (0.09678), m=30.19705 (0.5326). This probability
distribution was used to assign age to late-stage cases from the
WHO Atlas of HAT dataset when modelling DALY burden.
(TIF)
Figure S3 Probability distribution for rhodesiense HAT
mortality. A quadratic function was fit to mortality rates for
rhodesiense HAT cases taken from Berrang Ford et al. [36] using the
qfit function in STATA 11 software. Parameters: a = 0.0000248,
b =20.0016197, c = 0.0757683. Average mortality, weighted by
incidence = 0.058686.
(TIF)
Table S1 Uganda-specific life tables. 2000 and 2009 life
expectancy values were averaged and weighted by the sex ratio
shown in HAT case incidence, with 51.6% of cases being male
[36].
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Text S1 GBD 2010 revisions.
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